Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of escalated treatment regimens for intermediate- and high-risk oropharyngeal cancer
2014-003389-26Phase 3Suspended
- Sponsor
- University of Birmingham
- Start
- Jul 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cisplatin, carboplatin and durvalumab in oropharyngeal cancer, sponsored by University of Birmingham. Started Jul 2015; status: suspended.
02
Drugs
cisplatincarboplatindurvalumab
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on 2014-003389-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003389-26.